Bioventix has completed a US$1.4 million sell-down of founder’s equity
Bioventix Plc has raised funds through a sell-down of the founder’s equity.
Bioventix was founded in 2003 as a biotechnology company specializing in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics such as clinical blood testing.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker in respect of the sell-down of the founder’s equity.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreBackspin has completed a mandatory public tender offer for the shares of Spindox
Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn more